RBMX like 2Genealiases: HNRNPG-T · HNRNPGT · HNRPGT
Q-omics provides the consensus-scored RBMXL2 profile across patient tissues and cancer cell-line models. RBMXL2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RBMXL2 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, RBMXL2 RNA expression shows 12,403 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, LUSC, and TGCT as cancer lineages where RBMXL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMXL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMXL2 survival associations across molecular data types. RBMXL2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMXL2 RNA expression–survival associations across cancer types. High RBMXL2 expression shows unfavorable associations in THCA, but favorable associations in UCS, ESCA, SCLC, SKCM and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for RBMXL2 RNA expression.
This table summarizes RBMXL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMXL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMXL2 shows lower tumor expression in LUSC, KICH, LUAD, THCA, BRCA and UCEC. The LUSC box plot shows higher RBMXL2 RNA expression in normal versus tumor tissue (log2 FC = −0.110, t-test p < 0.001).
This table shows molecular features associated with RBMXL2 in patient tissues and cancer cell lines. In patient samples, RBMXL2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RBMXL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
